Kornimate/medical-research-clean huggingface dataset:
setting benchmarks for transsphenoidal resection of pituitary adenomas

Conditions: Pituitary Adenoma; Pituitary Tumor; Pituitary Diseases

Summary: to conduct a retrospective multicenter cohort study to define benchmark values for best achievable outcomes following transsphenoidal resection of pituitary adenomas.

surgeons strive for the best possible outcome of their surgeries with the greatest possible chance for recovery of the patients. therefore, monitoring and quality improvement is increasingly important in surgery. for this purpose, different concepts were developed with the aim to assess best achievable results for several surgical procedures and reduce unwarranted variation between different centers. the concept of a benchmark establishes reference values which represents the best possible outcome of high-volume centers and can be used for comparison and improvement. in the past years, the concept of benchmarking attaches greater importance in the field of healthcare, especially in surgery. benchmark values are established within a patients' cohort for which the best possible outcome can be expected. to date, no valid concept exists to describe the outcome of patients after transsphenoidal resection of pituitary adenomas. the aim of our study is the establishment of robust and standardized outcome references after transsphenoidal surgery. after successful implantation of benchmarks from an international cohort of renowned centers, these data serve as reference values for the evaluation of novel surgical techniques and comparisons among centers or future clinical trials.

Eligibility criteria:
inclusion criteria: * patients who went through transsphenoidal resection of pituitary adenoma * including high-volume centres with ≥50 cases per year exclusion criteria: -
nutritional status among naïve hiv infected patients and hiv infected patients receiving highly active antiretroviral therapy

Conditions: HIV Infections

Summary: a prospective cross-sectional study evaluates nutritional status and its relationship to the related factors in thai hiv-infected patients who attending in out patient clinic.

a prospective cross-sectional study evaluates nutritional status and its relationship to the related factors in thai hiv-infected patients who attending in out patient clinic at the thai red cross aids research centre, bamrasnaradura infectious disease institute, surat thani hospital, khonkaen hospital, sanpathong hospital and the queen savang vadhana hospital at sri racha . general objective: to determine nutritional status among thai people living with hiv (plhiv). specific objective: 1. to assess nutritional problems including undernutrition, overnutrition and others such as lipodystrophy, dyslipidemia, hyperglycemia, cardiovascular disease, etc. among naïve hiv-infected patients and hiv-infected patients undergoing harrt by using abcdef approach: anthropometric, biochemical, clinical, dietary, exercise and family assessment. 2. to describe the relationship between the nutritional status and hiv disease staging and other related factors among naïve hiv-infected patients and hiv-infected patients undergoing harrt. 3. to describe the prevalence of cvd and its relationship to cardiac risk factors 4. to validate the community screening tool developed by the thai nutrition taskforce in hiv (tnt-hiv) by assessing the correlation of this tool and nutritional status.

Eligibility criteria:
inclusion criteria: * hiv positive * 18 years of age or older * receiving ongoing care as part of the anonymous clinic, trcarc, the antiretroviral therapy clinics at bamrasnaradura infectious disease institute, surat thani hospital, khonkaen hospital, sanpathong hospital and the queen savang vadhana hospital at sri racha. * either naïve hiv-infected patients and hiv-infected patients undergoing harrt exclusion criteria: * hiv negative * patient who had active aids-related disorders within three months before participate the study * patients who are pregnant

Keywords: nutritional status nutritional situation
prevalence and predictive factors of portal vein thrombosis in patients with cirrhosis

Conditions: Liver Cirrhosis; Portal Vein Thrombosis

Summary: several studies have confirmed that patients with cirrhosis possess an imbalance in procoagulant versus anticoagulant activity due to increased factor viii and decreased protein c. moreover, in the last two decades there has been an increased recognition that not only bleeding but also thrombosis complicates the clinical course of cirrhosis. the prevalence and pathogenesis of portal vein thrombosis (pvt) in patients with cirrhosis without hepatocellular carcinoma are not clearly defined. the aim of this study is to assess the prevalence of portal vein thrombosis in patients with cirrhosis without hepatocellular carcinoma, and to prospectively assess the risk factors, outcome, and prognosis in these patients. the investigators plan to enroll two hundred patients with liver cirrhosis. the patients are going to follow up for one year and evaluate at baseline and every 6 months by liver function tests, coagulation test, upper abdomen ultrasound. all relevant clinical events will be evaluated at every follow up.


Eligibility criteria:
inclusion criteria: cirrhosis of any etiology and severity, aged 18-80 years, signed informed consent. exclusion criteria: hepatocellular carcinoma, other intrahepatic/extrahepatic cancers, documented history of congenital coagulation disorders, pregnancy, human immunodeficiency virus (hiv) positivity, recent (\<7 d) transfusion with blood products, use of anticoagulant/antiaggregation drugs in the past 10 d.
prospective epidemiological study of metastatic non small cell lung cancer (nsclc) in latin america

Conditions: Lung Cancer

Summary: to describe the overall survival of advanced nsclc in latin america.

* to describe demographic and socioeconomic characteristics of patients newly diagnosed with advanced nsclc * to describe diagnostic methods, pathological profile and disease stage at diagnosis of advanced nsclc * to describe the practice patterns of therapeutic agents for treatment of advanced nsclc * to describe treatment responses, progression and survival times. * to describe reasons for treatment discontinuation * to identify associations between patient demographics, socioeconomic, pathology, treatment sequences and overall survival; * to define the patient experience of advanced nsclc and identify unmet needs in their diagnose and treatment.

Eligibility criteria:
inclusion criteria: 1. patients aged 18 years or older; 2. newly diagnosed non-small cell lung cancer (nsclc) during the period of the study (which includes 3 months prior to site activation by lacog, although they can have received anti-cancer treatment during that time); 3. histologically or cytologically confirmed advanced nsclc: 1. stage iiib that progressed after curative therapy (chemoradiation and/or surgery); 2. stage iv metastatic disease (de novo or distant relapse) 4. any nsclc histological subtype and molecular mutation; 5. any eastern cooperative oncology group (ecog) performance status (0 to 4) at diagnosis; 6. patients assigned by treating physician to any therapy (i.e. chemotherapy, targeted agents, immunotherapy) or palliative care; 7. access to patient medical chart for data collection; 8. willing and able to provide written informed consent and privacy authorization for the release of personal health information.

Keywords: lung cancer
evaluation of the labcorp covid-19+flu+rsv test home collection kit

Conditions: COVID-19 Respiratory Infection; Influenza A; Influenza Type B; RSV Infection

Summary: to compare the results obtained by analysis of a self-collected anterior nasal (an) swab as part of the labcorp covid-19+flu+rsv test home collection kit to a healthcare provider (hcp)-collected an swab in patients with symptoms of viral respiratory infection consistent with influenza a (flu a), influenza b (flu b), respiratory syncytial virus (rsv) and/or sars-cov-2 (c-19).


Eligibility criteria:
inclusion criteria: * presents with symptoms of viral respiratory infection consistent with flu a, flu b, rsv and/or c-19; * subject can read and understand written instructions in english; and * subject is able, in the professional opinion of the investigator, to provide up to 18.5ml of whole blood at the clinic visit. note - the blood draw will be optional for subjects \<12 years of age. exclusion criteria: * no personal access to the internet and no email address * subject is 14-17 years of age and their parent or legal guardian is unable to supervise the collection of the an swab sample from the subject; * subject is \<14 years of age and their parent or legal guardian refuses to collect the an swab sample from the subject; or * previous participation in this protocol.
airway clearance technique of oscillation and lung expansion in bronchiectasis

Conditions: Bronchiectasis Adult

Summary: the goal of this prospective randomized controlled trial is to explore the efficacy and safety of oscillation and lung expansion-a airway clearance technology-in bronchiectasis. participants will receive oscillation and lung expansion or postural drainage randomly in this study. and the symptom, quality of life scores and amount of expectoration will be compared between the two groups.


Eligibility criteria:
inclusion criteria: * patients with acute exacerbation of bronchiectasis exclusion criteria: * haemoptysis greater than 50ml * state of endangerment * pneumothorax * lung surgery history within 6 months * severe heart, brain and nervous system diseases

Keywords: bronchiectasis airway clearance technique
evaluation of the exoskeleton atlas 2030 as robot-assisted physical therapy to children with neuromuscular diseases

Conditions: Cerebral Palsy; SMA II; Neuromuscular Diseases

Summary: this study aims to evaluate the safety, usability and acceptability of a motorized mobility assistance exoskeleton. the protocol explores the use of the motorized device during static and dynamic rehabilitation sessions focused on walking and functional activities, with the expectation of evaluating the safety and usability of the device in the population studied. the protocol has been focused on defining how the device can be used appropriately in this population in a safe and effective manner by rehabilitation specialists. the study also aims to assess the safety of clinical staff who implement the intervention.


Eligibility criteria:
inclusion criteria: * maximum user weight of 35 kg * thigh length (distance from the greater trochanter to the lateral condyle of the tibia) from 24 cm to 40 cm. * leg length (distance from the lateral condyle of the tibia to the lateral malleolus) from 23 to 39 cm. * pelvis width (between greater trochanters) from 24 to 35 cm. * ability to achieve ankle dorsiflexion to 90˚ * 20º or more hip flessum. * 20º or more knee flessum. * no allergies to any of the atlas materials: cotton, nylon, polyester, polyamide, polyethylene or propylene. * informed consent signed by legal guardians. * confirmed diagnosis of cerebral palsy or neuromuscular disease affecting walking ability at early development stages * stable medical condition with no changes in disease-specific medication in the last 6 months, and additional medication in the last month. * patient being followed according to the recommended standards for his or her illness * ability to maintain, spontaneously or with a brace, the head and trunk while standing and walking. * no need for daytime ventilation (have an oxygen saturation and pco2 with normal ambient oxygen * score on the fac scale between 1 and 4 points * not being able to walk without assistance exclusion criteria: * patient's inability to follow simple instructions and/or communicate discomfort. * invasive or non-invasive daytime ventilation. * orthostatic hypotension. * 20º or more hip flessum. * 20º or more knee flessum * scoliosis with a cobb angle of more than 25º that cannot wear a corset during the test. * severe skin injury to the lower extremities. * scheduled surgery (spine, extremities) during the period of the study or surgery performed (spine, extremities) in the last 6 months. * history of fracture without trauma. * history of traumatic bone fracture in lower limbs or pelvic girdle in the last 3 months * not receiving regular standing rehabilitation sessions. * absence of control of the head or trunk in an upright position without the possibility of wearing a corset during the use of the exoskeleton * refusal of the patient or legal guardian to include the child in the study. * skin problems (diseases, allergies, sensitivity ...) that prevent the use of exoskeleton accessories on the skin of patients.

Keywords: exoskeleton robot-assisted physical therapy atlas
high flow nasal oxygen during sedation

Conditions: Anesthesia; Cardiac Disease

Summary: the primary objective of this study is to test the hypothesis that using high flow nasal oxygen improves ventilation during cardiac implantable electronic device procedures performed with conscious sedation. a randomized controlled trial design will be used with participants randomized in a 1:1 ratio to oxygen supplementation through a standard facemask or high flow nasal oxygen.

high flow nasal oxygen (hfno) is increasingly regarded as a promising technology for oxygen delivery in critical care and anesthetic management. although promising, further high-quality studies examining the effects of using hfno during procedural sedation are required to inform decision-making regarding implementation of this new technology into practice. the 2018 guidelines from the american society of anesthesiology stated that there is insufficient evidence regarding which methods of supplemental oxygen administration (e.g., nasal cannula, face mask, or specialized devices such as hfno) are more effective. this trial will address this limitation in the evidence base specifically in regard to the efficacy of using hfno during conscious sedation in the cardiac catheterisation laboratory.

Eligibility criteria:
inclusion criteria: 1. adults undergoing an elective cardiac implantable electronic device procedure in the peter munk cardiac centre cardiac cath labs with conscious sedation administered by an anesthetic assistant (de novo and replacement/revision procedures). exclusion criteria: 1. under 16 years of age. 2. underlying condition requiring chronic oxygen supplementation. 3. diagnosed respiratory condition with confirmed current hypercapnia. 4. pre-existing untreated pneumothorax. 5. transesophageal echocardiography planned for the procedure. 6. active nasal bleeding. 7. complete nasal obstruction. 8. recent upper airway surgery or base of skull fracture. 9. previous participation in the study.

Keywords: oxygen ventilation high-flow nasal oxygen hypercapnia respiratory depression respiratory compromise carbon dioxide transcutaneous carbon dioxide
transcutaneous autonomic modulation in thoracic surgery

Conditions: Atrial Fibrillation, Postoperative; Postoperative Complications; Inflammation

Summary: in this study, the investigators aim to determine whether non-invasive autonomic modulation decreases inflammation and complications after thoracic surgery. the investigators will test the hypothesis that low-level transcutaneous vagal nerve stimulation (llvns) during major thoracic surgery reduces inflammation and complications, particularly postoperative atrial fibrillation (poaf). this will be a prospective randomized pilot trial of 200 patients undergoing major thoracic surgery including lobectomy, bilobectomy, or pneumonectomy via either video-assisted thoracoscopic (vat) or open thoracotomy. patients will be randomized to receive ether a) llvns (n=100) or b) sham llvns (n=100) during their procedure. all patients will receive standardized anesthetic, surgical, and post-surgical care. the primary outcome in this study will be time to occurrence of in-hospital poaf, which will be compared between groups using cox proportional hazards models. secondary outcomes will be icu and hospital length of stay, postoperative morbidity, postoperative mortality, and serologic markers of inflammation.


Eligibility criteria:
inclusion criteria: * major thoracic surgery (lobectomy, bilobectomy, or pneumonectomy via either video-assisted thoracoscopic (vat) or open thoracotomy) exclusion criteria: * patients \>90 or \<40 years of age * chronic atrial fibrillation * prior splenectomy * preoperative inotropic support * hepatic or renal failure * currently receiving vagal nerve stimulation therapy * taking centrally-acting cholinergic medications (tacrine, donepezil, rivastigmine) * high-grade atrioventricular block (\>2nd degree atrioventricular blockade)

Keywords: autonomic vagal nerve stimulation postoperative atrial fibrillation
clinical study of da-007 for the treatment of chemotherapy induced alopecia

Conditions: Chemotherapy Induced Alopecia; Chemotherapy Side Effects

Summary: clinical study of da-007 as a treatment for chemotherapy induced alopecia

chemotherapy induced alopecia (cia) is a common adverse event of oncological treatment. the significant psychological burden of cia, particularly in women, leads some (\~8%) to reject life saving therapeutic regimens. several studies have demonstrated the effectiveness of scalp vasoconstriction as a prophylactic treatment for cia. recently, us food and drug administration (fda) approved a scalp-cooling device as a prophylactic treatment for cia. scalp cooling results in reduced local blood perfusion and consequently reduced chemotherapeutic agents reaching the hair follicle niche; however, scalp cooling requires prolongation of the time required to attend the chemotherapy unit (\>2 hrs) as well as common adverse events including intolerance to cold. a previous study demonstrated that the α1 agonist, phenylephrine hydrochloride, applied topically can penetrate the scalp and bind α1 receptors. as such, a topically applied α1 agonist would reduce scalp blood perfusion. a novel formula (da-007), containing an α1 agonist, that can also penetrate the scalp and bind α1 receptors. the aim of the study is to test the hypothesis that da-007 can reduce scalp blood perfusion and thus reduce hair loss due to chemotherapy.

Eligibility criteria:
inclusion criteria: * diagnosed with stage i or stage ii breast cancer * scheduled but not begun, at least 4 cycles of taxane and/or anthracycline-based chemotherapy. * ages 18-65 * able to give informed consent exclusion criteria: * resting blood pressure outside the range of 105-140/ 55-99 * uncontrolled or severe hypertension * female pattern hair loss or hair loss disorder * folliculitis * scalp psoriasis * seborrheic dermatitis * inflammatory scalp conditions such as lichen planopillaris * subjects wearing wigs prior to chemotherapy * use of mao inhibitors * unable to provide consent or make allotted clinical visits

Keywords: chemotherapy induced alopecia chemotherapy alopecia
study to compare the safety and pharmacokinetics of ckd-390 tablet with viread® tablet

Conditions: Chronic Hepatitis B

Summary: the purpose of this study is to compare the safety and pharmacokinetics of ckd-390(tenofovir disoproxil aspartate) and viread® tablet(tenofovir disoproxil fumarate) in healthy male volunteers.

a randomized, open-label, single-dosing, 2x2 crossover study to compare the safety and pharmacokinetics of ckd-390 tablet (tenofovir disoproxil aspartate) with viread® tablet (tenofovir disoproxil fumarate) in healthy male volunteers

Eligibility criteria:
inclusion criteria: 1. healthy male volunteer in the age of 19-45 2. body weight ≥ 55kg and in the range of calculated ideal body weight ± 20% 3. subject without a hereditary problems, chronic disease and morbid symptom 4. subject who sign on an informed consent form willingly exclusion criteria: 1. clinically significant disease with hepatobiliary, nephrological, gastrointestinal, respiratory, hepato-oncological, endocrine, urogenital, neurologic, psychiatric, musculoskeletal, immune, otorhinolaryngological, cardiovascular system 2. gastrointestinal disease(crohn's disease, ulcer, acute/chronic pancreatitis) or gastrointestinal surgery(except for appendectomy or herniotomy) 3. hypersensitivity reaction or clinically significant hypersensitivity reaction in the history of drugs or additives 4. galactose intolerance, lapp lactase deficiency or glucose-galactose malabsorption 5. sitting systolic blood pressure \> 140mmhg or \< 100mmhg, sitting diastolic blood pressure ≥ 90mmhg or \< 60mmhg, pulse ≥ 100 beats per minute 6. aspartate aminotransferase, alanine aminotransferase, total bilirubin \> 2 x upper limit of normal range 7. have the result of creatinine clearance is less than 50ml/min(cockcroft-gault equation applicable) 8. the history of drug abuse or drug abuse showed a positive for urine drug test 9. subject treated metabolizing enzyme inducers or inhibitors including barbiturates within 1 month 10. subject treated ethical the counter or herbal medicine within 2 weeks, over-the-counter or vitamin within 1 week 11. taking drugs have received any other investigational drug within 3 months prior to the first dosing 12. whole blood donation within 2 months prior to the first dosing or component blood donation within 1 months prior to the first dosing or blood transfusion within 1 month 13. continuously taking excessive alcohol (\> 21 units/week; 1 unit = 10g of pure alcohol) or cannot stop drinking from 24 hours before admission to discharge 14. cigarette \> 10 cigarettes a day on average for recent 3 months 15. subjects with planning of dental treatment (tooth extraction, endodontic treatment etc.) and any surgery (aesthetic operation, laser in-situ keratomileusis, laser assisted sub-epithelial keratomileusis etc.) from signed on an informed consent form to post-study visit 16. an impossible one who participants in clinical trial by investigator's decision including laboratory test result or another reason

Keywords: chronic hepatitis b virus, hiv-1 infection healthy male volunteer tenofovir disoproxil fumarate
biochemotherapy and bevacizumab followed by consolidation therapy with ipilimumab for metastatic melanoma

Conditions: Metastatic Melanoma

Summary: a phase i-ii study of treatment of metastatic melanoma using induction therapy with biochemotherapy plus bevacizumab followed by consolidation therapy with ipilimumab (bbi).

a phase i-ii study of treatment of metastatic melanoma using induction therapy with biochemotherapy (temodar,cisplatin, velban,il2 and ifn)plus bevacizumab followed by consolidation therapy with ipilimumab (bbi)

Eligibility criteria:
inclusion criteria: 1. stage 4 or unresectable stage 3 metastatic melanoma with or without measurable disease 2. age 18-70 years old 3. adequate pulmonary and cardiac function for high-dose il-2 4. ps 0-2 5. previous ipilimumab therapy will not exclude patients, but patients with previous ipilimumab will have separate efficacy analysis exclusion criteria: 1. brain metastases 2. creatinine \> 2x uln; bilirubin \> 3, wbc \< 3500, platelets \< 100,000, hgb \< 9 3. another active malignancy 4. gastrointestinal tract metastases except rectal metastases or primary are allowable 5. previous therapy for metastatic disease with chemotherapy of duration over 3 months or with high-dose interleukin-2 6. history of colitis or autoimmune disease such as lupus or rheumatoid arthritis 7. bevacizumab-related contraindications: hemoptysis or history of severe bleeding, uncontrolled hypertension, proteinuria with protein/creatinine ratio \> 1, acute myocardial infarction within 6 months